The clinical application of ACE inhibitors in coronary artery disease

British Journal of Cardiology

Volumn 9, Issue 3, 2002, Pages 158-162

  Gomma, Abba ^a   Henderson, John ^a   Purcell, Henry ^a   Fox, Kim M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitors; Coronary artery disease; EUROPA; HOPE; PEACE

Indexed keywords

ALPHA TOCOPHEROL; BRADYKININ; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ANAMNESIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM LESION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NEUROENDOCRINE SYSTEM; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PHARMACOLOGICAL BLOCKING; PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; REVIEW; STROKE;

EID: 0036198742     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Formulating clinical strategies for angiotensin antagonism. A review of preclinical and clinical studies
2. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND study
3. Does the new ACE inhibitor cilazapril prevent restenosis after PTCA? Results of the MERCATOR study: A multicentre, randomized double-blind placebo-controlled trial
4. Effect of high doses of ACE inhibition on restenosis: Final results of the MARCATOR study
5. Baseline clinical and angiographic data in the quinapril ischaemic event (QUIET) trial
6. Effect of cilazapril on vascular restenosis after PTCA
7. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
8. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
9. The EUROPA Trial: Design, baseline demography and status of substudies
10. Prevention of events with ACE inhibitor (the PEACE study design)
11. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients
12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Result of the HOPE study and MICROHOPE substudy
13. Hyperinsulinaemia and the aldosterone and pressor responses to angiotensin II
14. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?